ES2615630T3 - Formulaciones sólidas que contienen resveratrol y ácidos grasos poliinsaturados omega-3 (n-3 PUFA) - Google Patents

Formulaciones sólidas que contienen resveratrol y ácidos grasos poliinsaturados omega-3 (n-3 PUFA) Download PDF

Info

Publication number
ES2615630T3
ES2615630T3 ES14001940.7T ES14001940T ES2615630T3 ES 2615630 T3 ES2615630 T3 ES 2615630T3 ES 14001940 T ES14001940 T ES 14001940T ES 2615630 T3 ES2615630 T3 ES 2615630T3
Authority
ES
Spain
Prior art keywords
pufa
fatty acids
composition according
omega
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14001940.7T
Other languages
English (en)
Spanish (es)
Inventor
Mosé Santaniello
Giuseppe Giannini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2615630T3 publication Critical patent/ES2615630T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
ES14001940.7T 2014-06-04 2014-06-04 Formulaciones sólidas que contienen resveratrol y ácidos grasos poliinsaturados omega-3 (n-3 PUFA) Active ES2615630T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14001940.7A EP2952180B1 (en) 2014-06-04 2014-06-04 Solid formulations containing resveratrol and omega-3 polyunsaturated fatty acids (n-3 PUFA)

Publications (1)

Publication Number Publication Date
ES2615630T3 true ES2615630T3 (es) 2017-06-07

Family

ID=50884650

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14001940.7T Active ES2615630T3 (es) 2014-06-04 2014-06-04 Formulaciones sólidas que contienen resveratrol y ácidos grasos poliinsaturados omega-3 (n-3 PUFA)

Country Status (14)

Country Link
US (1) US20170112791A1 (OSRAM)
EP (1) EP2952180B1 (OSRAM)
JP (1) JP2017522278A (OSRAM)
CN (1) CN106456587B (OSRAM)
AU (1) AU2015271278A1 (OSRAM)
CA (1) CA2943021A1 (OSRAM)
EA (1) EA032762B1 (OSRAM)
ES (1) ES2615630T3 (OSRAM)
MX (1) MX369782B (OSRAM)
PL (1) PL2952180T3 (OSRAM)
PT (1) PT2952180T (OSRAM)
SI (1) SI2952180T1 (OSRAM)
UA (1) UA119174C2 (OSRAM)
WO (1) WO2015185239A1 (OSRAM)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100384548C (zh) * 2002-08-14 2008-04-30 索莱有限责任公司 具有高液体负载的固体易流动粉末
ITRM20020562A1 (it) 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
WO2009034124A1 (en) * 2007-09-12 2009-03-19 Novozymes A/S Omega-3 stabilisation towards oxidation
KR101100078B1 (ko) * 2008-03-27 2011-12-29 홉킨스바이오연구센터(주) 관절염 치료를 위한 약제학적 조성물
US9005608B2 (en) * 2009-03-24 2015-04-14 Adds Pharmaceuticals Llc Stabilized solubility-enhanced formulations for oral delivery
SG181446A1 (en) 2009-12-23 2012-07-30 Defiante Farmaceutica Sa Combination composition useful for treating cardiovascular diseases
US20110244031A1 (en) * 2010-03-31 2011-10-06 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations
IT1400695B1 (it) 2010-06-21 2013-06-28 Labomar S R L Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle.
WO2014041071A1 (en) * 2012-09-12 2014-03-20 Novaliq Gmbh Semifluorinated alkane compositions

Also Published As

Publication number Publication date
CA2943021A1 (en) 2015-12-10
MX2016013189A (es) 2017-01-16
CN106456587B (zh) 2020-03-20
AU2015271278A1 (en) 2016-11-10
PL2952180T3 (pl) 2017-05-31
WO2015185239A1 (en) 2015-12-10
CN106456587A (zh) 2017-02-22
US20170112791A1 (en) 2017-04-27
PT2952180T (pt) 2017-03-02
SI2952180T1 (sl) 2017-05-31
EA201692399A1 (ru) 2017-03-31
JP2017522278A (ja) 2017-08-10
EA032762B1 (ru) 2019-07-31
EP2952180B1 (en) 2017-01-25
MX369782B (es) 2019-11-21
UA119174C2 (uk) 2019-05-10
EP2952180A1 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
RU2709612C2 (ru) САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ
ES2841344T3 (es) Composición autoemulsionante de ácidos grasos omega-3
CA2974495C (en) .omega.-3 fatty acid self-emulsifying composition
ES2632967T3 (es) Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
CN102843922B (zh) 硝基脂肪酸–认知减退的神经保护和/或抑制
ES2613606T3 (es) Uso de derivados de ácidos grasos polinsaturados como medicamentos
ES2882192T3 (es) Combinaciones antiinflamatorias sinérgicas de astaxantina con licopeno y ácido carnósico
ES2643843T3 (es) Aplicación terapéutica de aceite de kril por vía parenteral
JP5626890B2 (ja) リポ酸のペレット組成物
ES2889874T3 (es) Tratamiento de neuropatía óptica y reducción del estrés oxidativo inducido por esteroides con sustancias polinsaturadas estabilizadas
Ghaeini Hesarooeyeh et al. Effect of resveratrol and curcumin and the potential synergism on hypertension: A mini‐review of human and animal model studies
WO2015087329A1 (en) Pectin based nanoparticles
CN101888837B (zh) 提高辅酶q10生物利用度的辅酶q10和大蒜油的组合物
ES2666836T3 (es) Formulaciones homogéneas que comprenden ácidos grasos poliinsaturados omega-3 (n-3 PUFA) y resveratrol para administración oral
ES2615630T3 (es) Formulaciones sólidas que contienen resveratrol y ácidos grasos poliinsaturados omega-3 (n-3 PUFA)
Hao et al. Potential benefits of orally deliverable silymarin-loaded spirulina platensis in mitigating alcoholic liver disease
JP6750831B2 (ja) 非アルコール性脂肪性肝疾患の処置
ES2308550T3 (es) Formulacion para administracion oral que ejerce un efecto reconstituyente sobre el sistema cardiovascular.
JP2016034918A (ja) 難水溶性抗酸化物質送達用組成物
Koga Stabilization of resveratrol through microencapsulation and incorporation into food products
WO2020008359A1 (en) A formulation for the prevention and as a coadjuvant treatment of neurodegenerative diseases
ES2802814B2 (es) Betaxantinas derivadas de triptofano y feniletilamina para uso en el tratamiento y/o prevencion del cancer
KR20240077381A (ko) 자가유화전달시스템을 이용한 지용성 생리활성성분의 흡수력 증대를 위한 조성물
WO2015185240A1 (en) Compositions containing simvastatin in omega-3 polyunsaturated fatty acids